Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Drugmakers Rise After Trump Pricing Rule Is Blocked

share with twitter share with LinkedIn share with facebook
share via e-mail
07/09/2019 | 01:44pm EDT

By Michael Wursthorn

Shares of drugmakers are rallying on hopes of greater pricing flexibility.

The blocking of a Trump administration rule that would have required drugmakers to disclose their products' pricing in television ads is expected to help pharmaceutical and biotech firms avoid some of the near-term pricing pressures that had weighed on those stocks in recent months.

Pharmaceutical stocks like Mylan NV, Allergan PLC and Merck & Co. rose at least 1.2% Tuesday, while biotech shops also rallied, including Regeneron Pharmaceuticals Inc., which added 1.5%.

The broad gains are being driven by a federal judge's decision late Monday to block the rule that would have required drugmakers to list prices to be included in direct-to-consumer TV ads for most prescription drugs covered by Medicare and Medicaid, Jefferies Group LLC health-care trader Jared Holz wrote in a recent note to clients. The move "bodes well for pricing efforts more broadly near term," he added, and investors are positioning themselves for the likelihood of pharmaceutical companies reporting solid second-quarter earnings results.

As of Tuesday, S&P 500 health-care stocks were projected to grow second-quarter earnings by 2.1% from a year earlier, the second-best rate of the broad index's 11 sectors, just behind utilities, according to FactSet. Most other sectors are expected to see earnings contract, with S&P 500 profits projected to fall 2.8%.

Health-care stocks also sport some of the market's most attractive valuations and could also be factoring into investors' interest. The S&P 500's health-care sector is currently trading at 15.5 times its earnings over the next 12 months, lower than nine other sectors except for financial stocks, according to FactSet.

The rule, completed in May and set to go into effect Tuesday before being blocked, was part of President Trump's broader effort to lower drug prices. Drugmakers argued the disclosure would confuse consumers into thinking they would have to pay more than they actually would for medications.

Still, some health-care companies remain vulnerable to new government regulation, something investors took notice of during Tuesday's session.

Meanwhile, reports that the White House will attempt to overhaul the kidney-care market as soon as Wednesday sent shares of dialysis-care providers sharply lower. Dialysis providers fell, with DaVita Inc. sliding 7.9% and Fresenius Medical Care AG shedding 5.5%. The losses pushed DaVita into negative territory for the year, while Fresenius remains up 15%.

The tug between gains and losses left the S&P 500's health-care sector up less than 0.1% in recent trading.

Write to Michael Wursthorn at Michael.Wursthorn@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.63% 159.25 Delayed Quote.19.15%
DAVITA -1.47% 56.97 Delayed Quote.10.71%
DJ INDUSTRIAL 0.96% 26135.79 Delayed Quote.12.04%
FRESENIUS MEDICAL CARE AG & CO. KGAA 2.39% 60.78 Delayed Quote.7.31%
FRESENIUS SE & CO. KGAA 2.86% 43.465 Delayed Quote.2.56%
MERCK AND COMPANY 1.33% 86.19 Delayed Quote.12.80%
MERCK KGAA AG 1.70% 95.92 Delayed Quote.6.60%
MYLAN NV 3.56% 19.19 Delayed Quote.-29.96%
NASDAQ 100 1.52% 7719.323313 Delayed Quote.20.13%
NASDAQ COMP. 1.35% 8002.812313 Delayed Quote.19.00%
PROCTER & GAMBLE HEALTH LTD 0.00%End-of-day quote.29.74%
REGENERON PHARMACEUTICALS 0.52% 298.38 Delayed Quote.-20.11%
S&P 500 1.21% 2923.65 Delayed Quote.15.23%
SANOFI 1.65% 77.24 Real-time Quote.2.09%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
08/15MERCK AND : AstraZeneca and Merck - LYNPARZA Phase 3 PAOLA-1 trial Met Primary E..
08/14MERCK AND : LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as F..
08/14ASTRAZENECA : Lynparza Phase III PAOLA-1 trial met primary endpoint
08/14AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study
08/12MARKET SNAPSHOT: Dow Closes 390 Points Lower, Loses Grip On 26,000 As 10-year..
08/12INTEC PHARMA : Reports Second Quarter 2019 Financial Results and Business Update
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
08/09VETERINARY VACCINE MARKET IS EXPECTE : Elanco, Merck, Hester Biosciences, MVP La..
More news
Financials (USD)
Sales 2019 45 867 M
EBIT 2019 15 606 M
Net income 2019 10 456 M
Debt 2019 19 507 M
Yield 2019 2,55%
P/E ratio 2019 21,8x
P/E ratio 2020 17,7x
EV / Sales2019 5,24x
EV / Sales2020 4,89x
Capitalization 221 B
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 18
Average target price 95,94  $
Last Close Price 86,19  $
Spread / Highest target 21,8%
Spread / Average Target 11,3%
Spread / Lowest Target 2,10%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY12.80%217 785
JOHNSON & JOHNSON1.79%346 681
ROCHE HOLDING LTD.12.24%238 299
NOVARTIS17.81%204 677
PFIZER-20.62%191 651
NOVO NORDISK AS16.65%122 509